Viking Therapeutics SG&A Expense (TTM) Analysis

Viking Therapeutics Inc (VKTX)

76.97 +1.21 (+1.60%) USD | NASDAQ | May 03, 16:00

76.86 -0.11 (-0.14%) After-Hours: 06:43

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2014. Upgrade now.

Date	Value
March 31, 2024	37.46M
December 31, 2023	37.02M
September 30, 2023	32.34M
June 30, 2023	27.69M
March 31, 2023	21.96M
December 31, 2022	16.12M
September 30, 2022	14.68M
June 30, 2022	13.05M
March 31, 2022	11.70M
December 31, 2021	10.70M
September 30, 2021	10.26M
June 30, 2021	10.37M
March 31, 2021	10.46M
December 31, 2020	10.73M
September 30, 2020	10.94M
June 30, 2020	10.37M
March 31, 2020	9.779M
December 31, 2019	9.128M
September 30, 2019	8.654M
June 30, 2019	8.201M
March 31, 2019	7.669M

Date	Value
December 31, 2018	7.121M
September 30, 2018	6.567M
June 30, 2018	6.087M
March 31, 2018	5.65M
December 31, 2017	5.329M
September 30, 2017	5.025M
June 30, 2017	4.958M
March 31, 2017	4.898M
December 31, 2016	4.847M
September 30, 2016	5.158M
June 30, 2016	5.779M
March 31, 2016	6.098M
December 31, 2015	5.030M
September 30, 2015	3.840M
June 30, 2015	2.419M
March 31, 2015	1.407M
December 31, 2014	1.245M
September 30, 2014	1.048M
June 30, 2014	0.69M
March 31, 2014	0.2167M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

8.201M

Minimum

Jun 2019

37.46M

Maximum

Mar 2024

16.08M

Average

10.83M

Median

SG&A Expense (TTM) Benchmarks